Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose CohortsGlobeNewsWire • 12/09/23
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin ResistGlobeNewsWire • 12/08/23
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular DisGlobeNewsWire • 12/07/23
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 DiabetesGlobeNewsWire • 12/05/23
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024GlobeNewsWire • 11/27/23
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular DiseaseGlobeNewsWire • 11/16/23
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)GlobeNewsWire • 11/08/23
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023GlobeNewsWire • 11/02/23
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 10/30/23
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)GlobeNewsWire • 10/17/23
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II StudyGlobeNewsWire • 09/28/23
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical OfficerGlobeNewsWire • 08/31/23
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate HighlightsGlobeNewsWire • 07/31/23
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient PopulationGlobeNewsWire • 07/24/23
BMEA FRAUD ALERT: Jakubowitz Law is Investigating Biomea Fusion, Inc. in Connection with Potential Violations of Federal Securities LawsPRNewsWire • 07/14/23
BMEA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Biomea Fusion, Inc.PRNewsWire • 07/13/23
INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Biomea Fusion, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: BMEA)PRNewsWire • 07/12/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/11/23
BMEA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Biomea Fusion, Inc.PRNewsWire • 07/11/23
BMEA ALERT: The Law Offices of Vincent Wong Investigate Biomea Fusion, Inc. for Potential Violations of Securities LawsPRNewsWire • 07/10/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/08/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/07/23
